Epistem Holdings Plc, a service company to the biotechnology industry, has appointed David Budd as chief executive officer, effective April 2016. Mr Budd will join from Leica Biosystems, a division of Danaher Corp. He has considerable medical diagnostics experience including in the market for point-of-care products. Prior to joining Leica, he directed marketing at Siemens Healthcare Diagnostics and led a business unit at Bayer Diagnostics UK.
Epistem announced the appointment on 13 January 2016.
Copyright 2016 Evernow Publishing Ltd